Alguacil-Ramos AM, et al. Rapid assessment of enhanced safety surveillance for influenza vaccine. Public Health. 2019 Feb 12;168:137-141
OBJECTIVES:
The enhanced safety surveillance for seasonal influenza vaccines established by the European Medicines Agency is required each season. Therefore, a registry capable of rapidly detecting and evaluating potential new safety concerns is needed. The aim of the study is to demonstrate the effectiveness of the vaccine information system of the Valencia region to make a rapid assessment of the influenza vaccine safety and describe the safety of the two vaccine types used in the 2017/2018 season.
STUDY DESIGN:
It is a population-based descriptive study.
METHODS:
Adverse events following immunization reports collected from 23rd October 2017 to 15th March 2018 were analyzed.
RESULTS:
A total of 55 adverse events for influenza vaccine were reported in season 2017/2018 with a reporting rate (RR) of 0.77 per 10,000 administered doses. Injection site reactions had a RR of 0.30 and 0.47 per 10,000 for subunit and adjuvanted vaccines, respectively. Differences per vaccine, sex, and risk group did not reach statistical significance.
CONCLUSIONS:
Reported events of the two influenza vaccine types used were similar than in other seasons and consistent with their safety profiles.
The enhanced safety surveillance for seasonal influenza vaccines established by the European Medicines Agency is required each season. Therefore, a registry capable of rapidly detecting and evaluating potential new safety concerns is needed. The aim of the study is to demonstrate the effectiveness of the vaccine information system of the Valencia region to make a rapid assessment of the influenza vaccine safety and describe the safety of the two vaccine types used in the 2017/2018 season.
STUDY DESIGN:
It is a population-based descriptive study.
METHODS:
Adverse events following immunization reports collected from 23rd October 2017 to 15th March 2018 were analyzed.
RESULTS:
A total of 55 adverse events for influenza vaccine were reported in season 2017/2018 with a reporting rate (RR) of 0.77 per 10,000 administered doses. Injection site reactions had a RR of 0.30 and 0.47 per 10,000 for subunit and adjuvanted vaccines, respectively. Differences per vaccine, sex, and risk group did not reach statistical significance.
CONCLUSIONS:
Reported events of the two influenza vaccine types used were similar than in other seasons and consistent with their safety profiles.
See Also:
Latest articles in those days:
- [preprint] Potential Pathways of Spread of Highly Pathogenic Avian Influenza A/H5N1 Clade 2.3.4.4b Across Dairy Farms in the United States 16 hours ago
- [preprint] The avian and human influenza A virus receptors sialic acid (SA)-α2,3 and SA-α2,6 are widely expressed in the bovine mammary gland 16 hours ago
- Repeatability and reproducibility of hunter-harvest sampling for avian influenza virus surveillance in Great Britain 17 hours ago
- The RBPome of influenza A virus NP-mRNA reveals a role for TDP-43 in viral replication 17 hours ago
- Novel Genotype of HA Clade 2.3.4.4b H5N8 Subtype High Pathogenicity Avian Influenza Virus Emerged at a Wintering Site of Migratory Birds in Japan, 2021/22 Winter 17 hours ago
[Go Top] [Close Window]